Results 31 to 40 of about 168,097 (250)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides

Frontiers in Cardiovascular Medicine, 2021
This review summarizes current knowledge regarding clinical epidemiology, pathophysiology, and prognosis for patients with HFmrEF in comparison to HFrEF and HFpEF. Although recommended treatments currently focus on aggressive management of comorbidities,
Kaiyuan Zhu, Teng Ma, Yang Su, Xin Pan, Rongrong Huang, Fenglei Zhang, Chunxi Yan, Dachun Xu, Dachun Xu   +8 more
doaj   +1 more source

Treatment of Heart Failure with Preserved Ejection Fraction [PDF]

, 2011
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90240/1/phco.31.3.312 ...
Barnes, Megan M., Bleske, Barry E., Dorsch, Michael P., Hummel, Scott L., Koelling, Todd M.   +4 more
core   +1 more source

Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction

Circulation, 2023
Background: The human heart primarily metabolizes fatty acids, and this decreases as alternative fuel use rises in heart failure with reduced ejection fraction (HFrEF).
V. Hahn, Christopher Petucci, Min-Soo Kim, K. Bedi, Hanghang Wang, Sumita Mishra, N. Koleini, Edwin J. Yoo, K. Margulies, Z. Arany, D. Kelly, D. Kass, K. Sharma   +12 more
semanticscholar   +1 more source

Geographical Variations in Patients with Heart Failure and Preserved Ejection Fraction: A Sub-Group Analysis of the APOLLON Registry

Balkan Medical Journal, 2019
Background: Clinical characteristics of patients with heart failure may vary geographically. However, limited data are available regarding the geographical differences of patients with heart failure and preserved ejection fraction.
Bülent Özlek, Eda Özlek, Hicaz Zencirkıran Ağuş, Mehmet Tekinalp, Serkan Kahraman, Oğuzhan Çelik, Cem Çil, Özcan Başaran, Volkan Doğan, Bedri Caner Kaya, İbrahim Rencüzoğulları, Altuğ Ösken, Lütfü Bekar, Mustafa Ozan Çakır, Yunus Çelik, Kadir Uğur Mert, Kadriye Memiç Sancar, Samet Sevinç, Gurbet Özge Mert, Murat Biteker   +19 more
doaj   +1 more source

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

European Journal of Heart Failure, 2023
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities.
S. Anker, Muhammad Shariq S Usman, M. Anker, J. Butler, M. Böhm, W. Abraham, M. Adamo, V. Chopra, M. Cicoira, F. Cosentino, G. Filippatos, E. Jankowska, L. Lund, B. Moura, W. Mullens, B. Pieske, P. Ponikowski, J. González-Juanatey, A. Rakisheva, G. Savarese, Petar M Seferović, J. Teerlink, C. Tschöpe, M. Volterrani, S. Haehling, Jian Zhang, Yuhui Zhang, J. Bauersachs, U. Landmesser, S. Zieroth, K. Tsioufis, A. Bayés‐Genís, O. Chioncel, F. Andreotti, E. Agabiti-Rosei, J. Merino, M. Metra, A. Coats, Giuseppe M C Rosano   +38 more
semanticscholar   +1 more source

Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options

Медицинский вестник Юга России, 2021
Type 2 diabetes mellitus is known to increase the risk of the development of heart failure with preserved ejection fraction and worsen its symptoms. To date, no specific treatment has been shown to reduce morbidity and mortality in patients with heart ...
A. A. Borisov, A. D. Gvozdeva, F. T. Ageev   +2 more
doaj   +1 more source

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. [PDF]

, 2015
BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients.
Anstrom, Kevin J., Borlaug, Barry A., Braunwald, Eugene, Chen, Horng H., Cole, Robert T., Felker, G. Michael, Joseph, Susan M., Koepp, Gabe A., Levine, James A., LeWinter, Martin M., McNulty, Steven E., Redfield, Margaret M., Reeves, Gordon R., Semigran, Marc J., Shah, Monica R, Shah, Sanjiv J., Tang, W.H. Wilson, Tedford, Ryan J., Velazquez, Eric J.   +18 more
core   +2 more sources

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

European Heart Journal, 2023
Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but ...
M. Vaduganathan, R. Mentz, B. Claggett, Z. Miao, Ian J. Kulac, Jonathan H. Ward, A. Hernandez, D. Morrow, R. Starling, E. Velazquez, K. Williamson, Akshay S. Desai, S. Zieroth, M. Lefkowitz, J. McMurray, E. Braunwald, S. Solomon   +16 more
semanticscholar   +1 more source

Biomarkers in Heart Failure with Preserved Ejection Fraction

Cardiac Failure Review, 2022
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous disorder developing from multiple aetiologies with overlapping pathophysiological mechanisms.
Antoni Bayes-Genis, Germán Cediel, Mar Domingo, Pau Codina, Evelyn Santiago, Josep Lupón   +5 more
doaj   +1 more source

Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction [PDF]

, 2015
Reduced exercise tolerance is an independent predictor of hospital readmission and mortality in patients with heart failure (HF). Exercise training for HF patients is well established as an adjunct therapy, and there is sufficient evidence to support the
Goh, CY, Hare, David L, Levinger, Itamar, Ul Haq, MA, Wong, C   +4 more
core   +2 more sources